Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit

Matthew D Hall; James M Anderson; Annaliesa Anderson; David Baker; Jay Bradner; Kyle R Brimacombe; Elizabeth A Campbell; Kizzmekia S Corbett; Kara Carter; Sara Cherry; Lillian Chiang; Tomas Cihlar; Emmie de Wit; Mark Denison; Matthew Disney; Courtney V Fletcher; Stephanie L Ford-Scheimer; Matthias Götte; Abigail C Grossman; Frederick G Hayden; Daria J Hazuda; Charlotte A Lanteri; Hilary Marston; Andrew D Mesecar; Stephanie Moore; Jennifer O Nwankwo; Jules O'Rear; George Painter; Kumar Singh Saikatendu; Celia A Schiffer; Timothy P Sheahan; Pei-Yong Shi; Hugh D Smyth; Michael J Sofia; Marla Weetall; Sandra K Weller; Richard Whitley; Anthony S Fauci; Christopher P Austin; Francis S Collins; Anthony J Conley; Mindy I Davis

doi:10.1093/infdis/jiab305

Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit

J Infect Dis. 2021 Jul 15;224(Supplement_1):S1-S21. doi: 10.1093/infdis/jiab305.

Authors

Matthew D Hall¹, James M Anderson², Annaliesa Anderson³, David Baker⁴, Jay Bradner⁵, Kyle R Brimacombe¹, Elizabeth A Campbell⁶, Kizzmekia S Corbett⁷, Kara Carter⁸, Sara Cherry⁹, Lillian Chiang¹⁰, Tomas Cihlar¹¹, Emmie de Wit¹², Mark Denison¹³, Matthew Disney¹⁴, Courtney V Fletcher¹⁵, Stephanie L Ford-Scheimer¹, Matthias Götte¹⁶, Abigail C Grossman¹, Frederick G Hayden¹⁷, Daria J Hazuda¹⁸, Charlotte A Lanteri¹⁹, Hilary Marston²⁰, Andrew D Mesecar²¹, Stephanie Moore²², Jennifer O Nwankwo²³, Jules O'Rear²⁴, George Painter²⁵, Kumar Singh Saikatendu²⁶, Celia A Schiffer²⁷, Timothy P Sheahan²⁸, Pei-Yong Shi²⁹, Hugh D Smyth³⁰, Michael J Sofia³¹, Marla Weetall³², Sandra K Weller³³, Richard Whitley²², Anthony S Fauci²⁰, Christopher P Austin¹, Francis S Collins², Anthony J Conley²⁰, Mindy I Davis²⁰

Affiliations

¹ National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA.
² Office of the Director, National Institutes of Health, Bethesda, Maryland, USA.
³ Pfizer Vaccine Research and Development, Pfizer, Pearl River, New York, USA.
⁴ University of Washington, Seattle, Washington, USA.
⁵ Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA.
⁶ The Rockefeller University, New York, New York, USA.
⁷ Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
⁸ Evotec, Lyon, France.
⁹ University of Pennsylvania, Philadelphia, Pennsylvania, USA.
¹⁰ Evrys Bio, Doylestown, Pennsylvania, USA.
¹¹ Gilead Sciences, Foster City, California, USA.
¹² Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
¹³ Vanderbilt University, Nashville, Tennessee, USA.
¹⁴ Scripps Research, Jupiter, Florida, USA.
¹⁵ University of Nebraska Medical Center, Omaha, Nebraska, USA.
¹⁶ University of Alberta, Edmonton, Alberta, Canada.
¹⁷ University of Virginia, Charlottesville, Virginia, USA.
¹⁸ Merck & Co, Inc, Kenilworth, New Jersey, USA.
¹⁹ Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
²⁰ National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
²¹ Purdue University, West Lafayette, Indiana, USA.
²² University of Alabama at Birmingham, Birmingham, Alabama, USA.
²³ 1910 Genetics, Inc, Cambridge, Massachusetts, USA.
²⁴ US Food and Drug Administration, Silver Spring, Maryland, USA.
²⁵ Emory University, Atlanta, Georgia, USA.
²⁶ Takeda California, Inc, San Diego, California, USA.
²⁷ University of Massachusetts Medical School, Worcester, Massachusetts, USA.
²⁸ Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, USA.
²⁹ University of Texas Medical Branch, Galveston, Texas, USA.
³⁰ University of Texas at Austin, Austin, Texas, USA.
³¹ Arbutus Biopharma, Inc, Warminster, Pennsylvania, USA.
³² PTC Therapeutics, Inc, South Plainfield, New Jersey, USA.
³³ University of Connecticut School of Medicine, Farmington, Connecticut, USA.

Abstract

The NIH Virtual SARS-CoV-2 Antiviral Summit, held on 6 November 2020, was organized to provide an overview on the status and challenges in developing antiviral therapeutics for coronavirus disease 2019 (COVID-19), including combinations of antivirals. Scientific experts from the public and private sectors convened virtually during a live videocast to discuss severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) targets for drug discovery as well as the preclinical tools needed to develop and evaluate effective small-molecule antivirals. The goals of the Summit were to review the current state of the science, identify unmet research needs, share insights and lessons learned from treating other infectious diseases, identify opportunities for public-private partnerships, and assist the research community in designing and developing antiviral therapeutics. This report includes an overview of therapeutic approaches, individual panel summaries, and a summary of the discussions and perspectives on the challenges ahead for antiviral development.

Keywords: SARS-CoV-2; antiviral therapeutics; emerging modalities; preclinical; proteases; viral replication machinery.

Published by Oxford University Press for the Infectious Diseases Society of America 2021.

Publication types

Congress

MeSH terms

Antiviral Agents / pharmacology
Antiviral Agents / therapeutic use*
COVID-19 / virology
COVID-19 Drug Treatment*
Drug Development
Humans
National Institutes of Health (U.S.)
Peptide Hydrolases / metabolism
Protease Inhibitors / pharmacology
Protease Inhibitors / therapeutic use
SARS-CoV-2 / drug effects*
United States
Virus Replication / drug effects

Substances

Antiviral Agents
Protease Inhibitors
Peptide Hydrolases

Abstract

Publication types

MeSH terms

Substances

Grants and funding